Opko acquires Aquashunt maker

Article

Vidus Ocular, Inc, the developer of the Aquashunt device for glaucoma, has been acquired by OPKO Health, Inc.

Vidus Ocular, Inc, the developer of the Aquashunt device for glaucoma, has been acquired by OPKO Health, Inc.

Aquashunt is an implantable device designed to reduce intraocular pressure physiologically. Currently in the preclinical stage, in vivo studies are anticipated to commence towards the end of the year.

"We believe the acquisition of Vidus Ocular is an excellent strategic fit with our ophthalmics business, providing us with the potential to market an innovative product that addresses a serious disease affecting millions of people," said Dr Naveed Shams, Chief Medical Officer and Senior Vice President of Research and Development of OPKO.

Related Videos
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
Dr Mary Elizabeth Hartnett speaks with David Hutton of Ophthalmology Times
Esen K. Akpek, MD, Professor at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, converses via zoom with David Hutton of Ophthalmology Times
Dr Ali Erginay discusses his EURETINA presentation
© 2023 MJH Life Sciences

All rights reserved.